Abstract:Introduction: Ovarian cancer is still the leading cause of death among all gynaecological cancers in developed countries. High-grade serous ovarian cancer patients (HGSOC) with platinum-resistant or refractory disease have limited therapeutic options thus very poor prognosis. Early identification of these patients could limit useless undesirable effects and explore more effective therapeutic options. Short-term ex vivo assays might address such unmet needs, providing a truly personalized approach. Methods: Eleven advanced HGSOC patients have been enrolled. At the time of primary debulking surgery, tumor biopsies from different tumor anatomic sites (omentum and/or peritoneum) have been collected and divided in two sections: one section has been included in OCT and then processed for H&E staining, the other section has been cut into thin 350 μm sections by a McIlwain tissue chopper and cultured in a liquid-air interface using semi-porous tissue culture inserts. At least three representative organotypic tumor slices have been harvested at different culture time points (T0-T5) and fixed in 10% buffered formalin before embedding in paraffin. To evaluate histopathological and immunohistochemical features of HGSOC tumor, H&E staining and Wilm's tumor protein (WT1), p16, Cytokeratin 7, p53, Ki-67, PAX-8 immunostaining have been performed on organotypic tumor slices and for comparison on corresponding uncut tumor biopsy. In addition, a label-free two-photon fluorescence microscopy approach have been applied to monitor changes in the Redox Ratio (RR), calculated as, representative of metabolic modifications inside the organotypic tumour slices. This functional analysis has been matched with multiplex spatial profiling using specific markers such as EpCAM/CD326 for the epithelial compartment, α-SMA for the stromal compartment, CD45 for the immune compartment, cleaved Caspase 3 and cytochrome C for the apoptosis, Ki-67 as proliferation index. Results: The first characterization phase has been concluded on selected patients' samples. Histopatological and immunoistochemical analysis have shown that organotypic tumors slices retained HGSOC features between the beginning and the end of the culture. When comparing with the uncut tumor biopsy, we have assessed that organotypic tumors slices maintain tumor heterogeneity. The approach based on metabolic imaging have highlighted the presence of different areas inside the tissue, with metabolic features remaining stable at the beginning and at the end of the culture. Treatment of organotypic tumors slices with cytotoxic agents, PARP inhibitors and immunotherapy is ongoing to evaluate drug response in terms of cell viability and metabolic rate. Conclusion: The proposed preclinical model seems promising and suitable for mimicking the in vivo tumor features. Further analyses are ongoing to evaluate the feasibility of organotypic tumor slices cultures as patient avatar for functional drug screening. Citation Format: Rita Trozzi, Camilla Nero, Marianna Buttarelli, Francesca Sillano, Cristian Ripoli, Raimondo Sollazzo, Giada Bianchetti, Donatella Lucchetti, Alessandro Sgambato, Claudio Grassi, Marco De Spirito, Giovanni Scambia. Ovarian tumor organotypic slices cultures for functional drug screening (TOSCA) [abstract]. In: Proceedings of the AACR Special Conference on Ovarian Cancer; 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_2) nr A092.

High-throughput screening in colorectal cancer tissue-originated spheroids

Colorectal Cancer Tissue-Originated Spheroids Reveal Tumor Intrinsic Signaling Pathways and Mimic Patient Clinical Chemotherapeutic Response As a Rapid and Valid Model

Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer

Patient-Derived Organoids of Colorectal Cancer: A Useful Tool for Personalized Medicine

High-throughput solutions in tumor organoids: From culture to drug screening

Establishment of Organoid Models Based on a Nested Array Chip for Fast and Reproducible Drug Testing in Colorectal Cancer Therapy

Grouped-seq for integrated phenotypic and transcriptomic screening of patient-derived tumor organoids

Spheroids and organoids derived from colorectal cancer as tools for in vitro drug screening

Abstract 221: Novel organotypic patient derived primary tumor tissues for oncology drug safety and efficacy studies

Drug repurposing screening and mechanism analysis based on human colorectal cancer organoids

Drug screening model meets cancer organoid technology

A Tumor‐Organoid‐Based Precision Medicine Platform for the Prediction of Drug Sensitivity of Colorectal Cancer

Abstract 4247: Miniaturizing patient-derived organoid screening assays for predictive drug testing

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Organoid Culture of Isolated Cells from Patient-derived Tissues with Colorectal Cancer

Abstract A092: Ovarian tumor organotypic slices cultures for functional drug screening (TOSCA)

Applications for Colon Organoid Models in Cancer Research

Incorporating Tumor Genomic Profiling and Circulating Tumor Cell-derived Organoids into Clinical Practice for Gastrointestinal Cancers

Genomic characteristics and drug screening among organoids derived fromnon-small celllung cancer patients

Patient-Derived Ex Vivo Cultures and Endpoint Assays with Surrogate Biomarkers in Functional Testing for Prediction of Therapeutic Response

Drug cytotoxicity screening using human intestinal organoids propagated with extensive cost-reduction strategies